PBI-1402

PBI-1402 Uses, Dosage, Side Effects, Food Interaction and all others data.

PBI-1402 is a small molecule synthetic compound with oralBioavailability. The compound activates neutrophils, enhancing their survival and activation with comparable efficacy to GM-CSF, G-CSF and EPO, which are currently used to treat anemia. However, it has been shown that when co-administered with these compounds, effects are additive, making PBI-1402 an excellent candidate for combination therapy and asserting its independent mechanism of action. PBI-1402 appears to work on the PMN pathway, but its specific binding properties are not known. PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator. Since it stimulates immune activity, it has been considered as a candidate for cancer treatment as well as anemia.

PBI-1402 is a small molecule synthetic compound with oralBioavailability. The compound activates neutrophils, enhancing their survival and activation with comparable efficacy to GM-CSF, G-CSF and EPO, which are currently used to treat anemia. PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator.

Table Of contents

• PBI-1402
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	PBI-1402
Generic	PBI-1402
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Investigated for use/treatment in adverse effects (chemotherapy), anemia, and chemotherapy.

How PBI-1402 works

PBI-1402 activates neutrophils, enhancing their survival and activation with comparable efficacy to GM-CSF, G-CSF and EPO, which are currently used to treat anemia. However, it has been shown that when co-administered with these compounds, effects are additive, making PBI-1402 an excellent candidate for combination therapy and asserting its independent mechanism of action. PBI-1402 appears to work on the PMN pathway, but its specific binding properties are not known.

Innovators Monograph

You find simplified version here PBI-1402